ClinicalTrials.gg
CompletedNCT00606307Updated Dec 3, 2019Results posted

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

A Phase 2 interventional study of ITF2357 in Myeloproliferative Diseases, sponsored by Italfarmaco. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Polycythemia Vera with a site in Italy — 8 open to participants now, 15 under way, 3 of them phase 3. Polycythemia Vera · Italy.

Enrollment
28th of 31
29 · median 127
Started
2007
with 2 others
Phase 2
11 of 44
none open now
Registered
6th of 44
by date
Lead sponsor
5 of 44
Italfarmaco

Among the 44 studies in Polycythemia Vera with a site in Italy, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 2, and was the 6th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

8 of the 44 studies in Polycythemia Vera with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Polycythemia Vera with a site in Italy, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate efficacy and safety of ITF2357 in the treatment of patients with JAK2V617F positive myeloproliferative diseases [Polycythemia Vera (PV), Essential Thrombocytosis (ET), Myelofibrosis (MF)]. Efficacy was evaluated by ad hoc haematological and clinical criteria for PV and ET, and by internationally established response criteria (EUMNET criteria) for MF. Safety was evaluated by number of subjects experiencing an Adverse Event (AE), type, frequency, severity, timing and relatedness of AEs, including changes in vital signs and clinical laboratory results.

Secondary Objective:

To evaluate the JAK2 mutated allele burden by quantitative Real-Time Polymerase Chain Reaction (qRTPCR).

Read the detailed description

This is a non-randomized, open-label, Phase IIA pilot study testing efficacy and safety of ITF2357 in a population of patients with JAK2V617F positive myeloproliferative diseases. All recruited patients received an initial dose of 50 mg b.i.d. of ITF2357 that was subsequently escalated to 50 mg t.i.d. in case of lack of significant toxicity. Treatment lasted up to a maximum of 24 cumulative weeks of drug administration. The study was carried out in Italy. Enrolled patients were subjects of both genders, with an established diagnosis of polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) according to the revised WHO criteria.

03

Conditions studied

  • Myeloproliferative Diseases

Keywords

  • polycythemia vera (PV)
  • essential thrombocythemia (ET)
  • myelofibrosis (MF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Male or female, age ≥ 18 years
  • Confirmed diagnosis of PV/ET/MF according to the revised World Health Organisation criteria
  • JAK-2 V617F positivity
  • In need of cytoreductive therapy when hydroxyurea is not indicated (e.g. young patients) or when refractoriness to the drug is documented

Exclusion criteria

Exclusion Criteria:

  • Active bacterial or fungal infection requiring antimicrobial treatment on Day 1
  • Patients of without a negative pregnancy test prior to initiation of the study drug
  • Pregnancy or lactation
  • A marked baseline prolongation of /QTc interval (e.g. repeated demonstration of a QTc interval > 450 ms, according to Bazett's correction formula - see appendix G for the formula)
  • The use of concomitant medications that prolong the QT/QTc interval (see appendix F for full list)
  • Concomitant acute coronary syndromes; uncontrolled hypertension
  • (NYHA) Grade II or greater congestive heart failure
  • History of any cardiac arrhythmia requiring medication (irrespective of its severity)
  • A history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Active Epstein Barr Virus (EBV) infection (i.e. positive serology IgM)
  • Known infection
  • Active and/or C infection
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
  • (ECOG) performance status 3 or greater
  • count \<100x109/L within 14 days before enrolment
  • \<1.2x109/L within 14 days before enrolment
  • Percentage of blast cells in peripheral blood >10% within 14 days before enrolment
  • Serum creatinine >2xULN ()
  • Total serum >1.5xULN
  • Serum (aspartate aminotransferase) / ALT (alanine aminotransferase) > 3xULN
  • Interferon alpha within 14 days before enrolment
  • Hydroxyurea within 14 days before enrolment
  • Anagrelide within 7 days before enrolment
  • Any other investigational drug within 28 days before enrolment
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    ITF2357

    Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.

    Drug: ITF2357

Interventions

  • 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.

    Also known as: Givinostat

06

What researchers measure

Primary outcomes

  1. Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response

    Patients with Objective Response were defined as those patients achieving a complete, major, moderate or minor (only for Myelofibrosis patients) response during the experimental treatment course. The "best response" is reported hereunder by intensity of response.

    Time frame: Every single week from week 1 to week 24 of treatment

Secondary outcomes

  1. Change in JAK2 Mutated Allele Burden

    This outcome was assessed by quantitative real time Polymerase Chain Reaction (RT PCR). At each time point, the number of patients is the following: Screening: N=29 Week 12: N=20 Week 24: N=18 EOT: N=24. End of treatment corresponds to the last visit performed before treatment discontinuation.

    Time frame: At screening, at week 12, at week 24, at the end of treatment (EOT) visit

  2. Number of Subject Experiencing an Adverse Event

    An adverse event (AE) is any untoward occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The adverse events must to be followed to the end of study (28 days after the last study drug intake). A serious AE (SAE) is defined as an untoward (unfavourable) medical occurrence that at any dose results in death, or is life-threatening or requires inpatient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

    Time frame: At weekly visits (Days 8, 15, 22, 36, 43, 50, 64, 71, 78, 99, 127, 155); At monthly visits (Days 29, 57, 85 113, 141,169); at end of treatment visit

07

Results

Posted Dec 3, 2019
Limitations and caveats
Non reported

Participant flow

Participant flow — Overall Study
MilestoneITF2357
Started29
Completed18
Not completed11
Withdrew: Adverse event2
Withdrew: Withdrawal by subject2
Withdrew: Disease progression6
Withdrew: Qtc prolongation1

Outcome measures

PrimaryNumber of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response

Patients with Objective Response were defined as those patients achieving a complete, major, moderate or minor (only for Myelofibrosis patients) response during the experimental treatment course. The "best response" is reported hereunder by intensity of response.

Time frame:
Every single week from week 1 to week 24 of treatment
Reported as:
Count of participants · Participants
Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response
ParticipantsITF2357
complete responders2
major responders12
moderate responders2
minor responders1
non responders12
SecondaryChange in JAK2 Mutated Allele Burden

This outcome was assessed by quantitative real time Polymerase Chain Reaction (RT PCR). At each time point, the number of patients is the following: Screening: N=29 Week 12: N=20 Week 24: N=18 EOT: N=24. End of treatment corresponds to the last visit performed before treatment discontinuation.

Time frame:
At screening, at week 12, at week 24, at the end of treatment (EOT) visit
Reported as:
Mean · percentage of change in allele burden
Change in JAK2 Mutated Allele Burden
percentage of change in allele burdenITF2357
screening54.0 ± 19.7
week 1249.4 ± 20.1
week 2447.1 ± 20.0
EOT49.0 ± 21.5
SecondaryNumber of Subject Experiencing an Adverse Event

An adverse event (AE) is any untoward occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The adverse events must to be followed to the end of study (28 days after the last study drug intake). A serious AE (SAE) is defined as an untoward (unfavourable) medical occurrence that at any dose results in death, or is life-threatening or requires inpatient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

Time frame:
At weekly visits (Days 8, 15, 22, 36, 43, 50, 64, 71, 78, 99, 127, 155); At monthly visits (Days 29, 57, 85 113, 141,169); at end of treatment visit
Reported as:
Count of participants · Participants
Number of Subject Experiencing an Adverse Event
ParticipantsITF2357
number of patients with AE29
number of patients with serious AE3

Adverse events

Collected over At weekly visits (Days 8, 15, 22, 36, 43, 50, 64, 71, 78, 99, 127, 155); At monthly visits (Days 29, 57, 85 113, 141,169); at three-monthly visit (Day 85). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ITF23570/29 (0%)3/29 (10.3%)29/29 (100%)
Most frequent serious events
Most frequent serious events
EventITF2357
CellulitisInfections and infestations1/29
Localised infectionInfections and infestations1/29
MelenaGastrointestinal disorders1/29
Disease progressionGeneral disorders1/29
Most frequent other events
Showing 10 of 67
Most frequent other events
EventITF2357
DiarrhoeaGastrointestinal disorders18/29
Weight decreasedInvestigations12/29
AstheniaGeneral disorders9/29
PyrexiaHepatobiliary disorders8/29
AnaemiaBlood and lymphatic system disorders6/29
Abdominal painGastrointestinal disorders6/29
InfluenzaInfections and infestations5/29
Electrocardiogram QT prolongedInvestigations5/29
ThrombocytopeniaCardiac disorders3/29
Abdominal pain upperGastrointestinal disorders3/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)ITF2357
Mean55.6 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)ITF2357
Female14.0
Male15.0
Region of Enrollment
Region of Enrollment(participants)ITF2357
Italy29
08

Study locations

2 sites
  • Ospedali riuniti
    Bergamo, 24158, Italy
  • IRCCS - Pol. San Matteo
    Pavia, 27100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 11 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2008
First posted
Feb 1, 2008
Start
Dec 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Dec 3, 2019
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606307
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Feb 1, 2008
Start date
Dec 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Dec 3, 2019
Last update
Dec 3, 2019

Study contacts

tiziano oldoni, MD
study director · Italfarmaco
Alessandro Rambaldi, MD
principal investigator · A.O. Ospedale Papa Giovanni XXIII

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion